Sahar Barjesteh van Waalwijk van Doorn

Has grant

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Drug Delivery Drug Delivery professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Open

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Open Date: 2023-07-01

Close Date: 2028-06-30

Grant: Close

Leukemia-associated Chromosomal Abnormalities: the Role of Prenatal Exposure to Dietary Topoisomerase II Inhibitors and Mutation in the ATM Gene

Open Date: 2006-07-01

Close Date: 2008-06-30

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (2)

Åslaug Helland

Professor

University of Oslo

NORWAY

View details

Katarina Steen Carlsson

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sahar Barjesteh van Waalwijk van Doorn

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Interchangeability of immune checkpoint inhibitors: an urgent need for action

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC

Osimertinib with Chemotherapy in <i>EGFR</i>-Mutated NSCLC

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development

Collaborators (2)

Åslaug Helland

Katarina Steen Carlsson

Make your next move.